BB&T Capital Cuts PT on Foot Locker (FL) Following Nike 4Q Report, But Incrementally Positive
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
UBS Remains Bullish on Nike (NKE) Following 4Q Report
June 29, 2016 7:55 AM EDTUBS reiterated a Buy rating and $70.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. NKE reported EPS at $0.49, in line with UBS estimates, and $0.01 above the Street. Revenues missed estimates by only -1%.
Analyst Michael Binetti commented, "NKE reported F4Q EPS... More
BB&T Capital Reiterates Buy on Nike (NKE) Following 4Q Beat
June 29, 2016 7:27 AM EDTBB&T Capital reiterated a Buy rating and $70.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. NKE reported a slight $0.01 EPS beat compared to Street estimates. Reported revenue grew +6%, largely in line with estimates, driven by +DD ex-Fx growth in... More
After-Hours Stock Movers 06/28: (KMPH) (FUEL) Higher; (ESPR) (NKE) (ANTH) Lower (more...)
June 28, 2016 5:55 PM EDTToday's After-Hours Movers:
Esperion Therapeutics, Inc. (NASDAQ: ESPR) 25.2% LOWER; provided updates on the bempedoic acid (ETC-1002) clinical development program and regulatory plans... For the United States (U.S.), the Company engaged with the U.S. Food and Drug Administration (FDA or the Agency) resulting in alignment on the definition of statin intolerance, key design features of the CVOT, and the regulatory approval pathway for a CV disease risk reduction indication in statin intolerant patients for bempedoic acid. However, the FDA did not provide clarity on a... More
